Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
Category Archives: Hormone Refractory Disease
MDV 3100 Clinical Study
Question of the week: What’s the latest on the MDV 3100 clinical study? What is the mode of action of this oral drug? Video Blog Presentation: Dr. Celestia Higano will talk about the status of the drug and info about … Continue reading →
Stromal Targeted Therapy in Bone Metastatic Disease
The following question is for the Ask Dr Barken Call In Show on Tuesday, March 6th at 6pm Pacific Time. Dial 1-877-727-3301 to hear the program. Question of the week: When should I start treating my bone metastatic disease? … Continue reading →
New drug in the pipeline called Cabozantinib (XL184)
XL184 is a new drug that is being developed to treat metastatic prostate cancer in the bone. XL184 works by blocking the “angiogenesis,” or the growth of new blood vessels, to the tumor. Dr. Barken reviews briefly information from the … Continue reading →